echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Sinopharm Hyundai Ceftriaxone Sodium for Injection Obtained Marketing License in Malta

    Sinopharm Hyundai Ceftriaxone Sodium for Injection Obtained Marketing License in Malta

    • Last Update: 2021-09-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On September 3, Sinopharm Hyundai issued an announcement stating that DALI PharmaGmbH, a wholly-owned subsidiary established by its holding subsidiary Zhijun Pharmaceuticals in Germany, received the approval of the Malta Pharmaceutical Regulatory Authority to issue ceftriaxone sodium for injection (250mg/500mg/ 1g) Marketing authorization


    Its indication is that ceftriaxone sodium is a long-acting, broad-spectrum third-generation cephalosporin antibiotic.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.